期刊文献+

静脉注射多烯紫杉醇纳米混悬剂的制备及性质考察 被引量:8

Preparation of docetaxel nanosuspension and its intravenous injection
原文传递
导出
摘要 目的:研究了多烯紫杉醇纳米混悬剂的制备方法及理化性质。方法:采用沉淀-高压匀质法制备多烯紫杉醇纳米混悬剂,以混悬粒子的粒径分布为指标,采用单因素和正交试验优化了纳米混悬剂的制备工艺,并进行理化性质考察。结果:多烯紫杉醇纳米混悬剂的平均粒径为(184±80)nm,药物浓度可达到5 mg.mL-1,其饱和溶解度经测定为20.4μg.mL-1,是药物粗颗粒的3.15倍,48 h的体外累积溶出百分率是药物粗颗粒的3倍以上。结论:多烯紫杉醇纳米混悬剂改善了药物的体外溶出速率,增加了载药量,提高了制剂的生物安全性,可供静脉注射使用。 Objective:To prepare and study the docetaxel nanosuspension and its intravenous injection.Methods:The preparation parameters of docetaxel nanosuspension were optimized by the single factor and orthogonal design using precipitation-homogenization method.The size distribution of nano-crystals were utilized as index to evaluate the parameters of precipitating temperature,agitating velocity,phospholipids ratio,drug loading and homogenization parameters.Particle diameter,solubility and in vitro release profile were measured.Results:The particle diameter of the injection was(184±80) nm.The solubility of DCT nanosuspension was 20.4 μg·mL-1,3 times of drug particles.The in vitro release profile of the injection exhibited an obvious fast release character.Conclusion:A DCT nanosuspension intravenous injection with high solubility and fast release profile was produced via the precipitation-homogenization process precipitation-homogenization process.
出处 《中国新药杂志》 CAS CSCD 北大核心 2010年第17期1613-1615,1620,共4页 Chinese Journal of New Drugs
关键词 多西紫杉醇 纳米混悬剂 溶解度 溶出速率 docetaxel nanosuspensions solubility dissolution rate
  • 相关文献

参考文献8

  • 1宋沁馨,于立洁.多西他赛的临床应用进展[J].中国新药杂志,2001,10(12):900-903. 被引量:18
  • 2Food and Drug Administration. Physicians'Desk Reference [ M ]. 51th Edition. Rockville: Department of Public Hcalth Services, 1997:2204 - 2207.
  • 3WONG J, BRUGGER A, KHARE A, et al. Suspensions for intravenous (IV) injection:A review of development, preclinical and clinical aspects [ J ]. Adv Drug Deliv Rev, 2008,60 ( 8 ) : 939 - 954.
  • 4钱帅,张建军,高缘,周建平.纳米混悬剂研究进展[J].药学进展,2007,31(1):9-14. 被引量:16
  • 5KECKA CM, MULLER RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation[ J]. Eur J Pharm Biopharm ,2006,62( 1 ) :3 - 16.
  • 6JUNGHANNS JU, MULLER RH. Nanocrystal technology, drug delivery and clinical applications[J], lnt J Nanomedicine,2008,3 (3) :295 -309.
  • 7CASSELYN M,TARDIEU A. Birth and growth kinetics of brome mosaic virus microcrystals[ J]. Biophys J,2004,87 (4) :2737 - 2748.
  • 8KIPP JE. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs[J]. Int J Pharm,2004, 284( 1 -2) :109 - 122.

二级参考文献36

  • 1段磊,夏强,张晓佳,吴玉龙,许宁,顾宁.维甲酸纳米颗粒混悬剂的制备及对实验性增殖性玻璃体视网膜病变的预防作用[J].南京医科大学学报(自然科学版),2005,25(12):857-860. 被引量:3
  • 2Lipinski C A.Drug-like properties and the causes of poor solubility and poor permeability[J].J Pharmacol Toxicol Methods,2000,44(1):235-249.
  • 3Nystrm C.Dissolution properties of soluble drugs:theoretical background and possibilities to improve the dissolution behavior[M]// Müller R H,Benita S,Bhm B.Emulsions and Nanosuspensions for Formulation of Poorly Soluble Drugs.Stuttgart:Medpharm Scientific Publisher,1998.
  • 4Carstensen J T.Advanced Pharmaceutical Solids[M].New York:Marcel Dekker,2001.
  • 5Mosharraf S M,Nystrom C.The effect of particle size and shape on the surface special dissolution rate of micronized practically insoluble drugs[J].Int J Pharm,1995,122(1-2):35-47.
  • 6Grant D J W,Brittain H G.Solubility of pharmaceutical solids[M]// Brittain G.Physical Characterization of Pharmaceutical Solids.New York:Marce Dekker,1995.
  • 7Duchene D,Ponchel G.Bioadhesion of solid oral dosage form,why and how[J].Eur J Pharm Biopharm,1997,44(1):15-23.
  • 8Kreuter J,Potrov V E,Kharkevich D A,et al.Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after 1st delivery across the blood-brain barrier using surfactant coated nanoparticles[J].J Controlled Release,1997,49(1):81-87.
  • 9Muller R H,Jacobs C.Buparvaquone mucoadhesive nanosuspension:preparation,optimisation and long-term stability[J].Int J Pharm,2002,237(1-2):151-161.
  • 10Hernandez T N,Kayser O,Steckel H,et al.Characterization of nebulized bparvaquone nanosuspensions-effect of nebulization technology[J].J Drug Target,2005,13(8-9):499-507.

共引文献32

同被引文献109

引证文献8

二级引证文献58

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部